Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 1;50(1):1-4.
doi: 10.1097/DSS.0000000000003967. Epub 2023 Oct 4.

Postoperative Bleeding Complications Associated With Novel Oral Anticoagulants in Mohs Micrographic Surgery

Lauren M Fahmy  1 , Margaret L Dowd  2   3 , Eric Loesch  2 , Elizabeth M Denson  2 , Catherine E Pisano  2 , Faramarz H Samie  2
Affiliations

Postoperative Bleeding Complications Associated With Novel Oral Anticoagulants in Mohs Micrographic Surgery

Lauren M Fahmy et al. Dermatol Surg. .

Abstract

Background: Novel oral anticoagulants (NOACs) are commonly prescribed, recently developed anticoagulants, but limited data exist on NOAC-related bleeding complications in Mohs micrographic surgery (MMS).

Objective: To assess the risk of postoperative bleeding in patients taking NOACs compared with patients taking no antithrombotic medications.

Methods/materials: A 5-year retrospective chart review of all MMS cases performed by a single surgeon was conducted. Patient and surgery characteristics, anticoagulant use, and bleeding complications were recorded.

Results: Two thousand one hundred eighty-one MMS cases in 1,545 patients were included. There were 696/2,181 cases in which patients were taking at least 1 antithrombotic medication, with 149 on NOAC monotherapy and 15 on NOAC and aspirin combination therapy. Bleeding complications occurred in 22/2,181 cases. Patients on NOAC monotherapy did not have an increased risk of bleeding complications compared with patients on no antithrombotic medications (odds ratio [OR]:1.70, 95% confidence interval [CI]: 0.36-7.97, p = .50). In contrast, patients on NOAC and aspirin combination therapy exhibited an increased bleeding risk (OR: 20.5, 95% CI: 3.99-105.7, p < .001).

Conclusion: Novel oral anticoagulant use alone during MMS was not associated with an increased postoperative bleeding risk, supporting the safety of continuing NOAC therapy during MMS. However, NOAC and aspirin combination therapy was associated with a high postoperative bleeding risk. Nonetheless, these bleeding events did not lead to adverse long-term outcomes.

PubMed Disclaimer

References

    1. Bordeaux JS, Martires KJ, Goldberg D, Pattee SF, et al. Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications. J Am Acad Dermatol 2011;65:576–83.
    1. Callahan S, Goldsberry A, Kim G, Yoo S. The management of antithrombotic medication in skin surgery. Dermatol Surg 2012;38:1417–26.
    1. Chen A, Albertini JG, Bordeaux JS, Chen MW, et al. Evidence-based clinical practice guideline: Reconstruction after skin cancer resection. J Am Acad Dermatol 2021;85:423–41.
    1. Plovanich M, Mostaghimi A. Novel oral anticoagulants: what dermatologists need to know. J Am Acad Dermatol 2015;72:535–40.
    1. Eilers REJ, Goldenberg A, Cowan NL, Basu P, et al. A retrospective assessment of postoperative bleeding complications in anticoagulated patients following Mohs micrographic surgery. Dermatol Surg 2018;44:504–11.

MeSH terms

LinkOut - more resources